Replies to post #11183 on ANI Pharmaceuticals (ANIP)

[rgshredder]

Cantor Fitzgerald analyst Brandon Folkes downgraded ANI Pharmaceuticals to Neutral from Overweight with a price target of $40, down from $78. The analyst sees uncertainty around the strategy that a new permanent CEO will bring. This, along with the recent FDA refuse to file letter of Cortrophin Gel, and the uncertainty that COVID-19 has placed on all company base businesses, warrants a cautious approach pending more visibility, Folkes tells investors in a research note.
-RG